Skip to main content

Identification and validation of novel pharmaceutical drug targets for cardiovascular disease

Objective

"Cardiovascular disease (CVD) is one of the major diseases in Europe and the Western world, killing over 2 million people per year in Europe alone and is the foremost cause of premature mortality and disability-adjusted life years, representing an annual economic cost of ∼€ 192 billion in direct and indirect healthcare expenses. The available therapies are insufficient to fulfill the need. The introduction of statins has reduced morbidity and mortality of atherosclerosis by 30%, however a large untreatable residual cardiovascularrisk remains even in cohorts of treated patients. Currently, many targets for CVD treatment have been selected based on mechanism of action and inference of functions in cellular models to clinical systems, and lack the rigorous clinical validation needed to maximize the chance for successful clinical drug development. Consequently, new drugs that modulate the activity of such targets fail later in clinical development by lack of efficacy or induction of safety liabilities due to off-target effects. To increase the success rate for clinical development of novel therapies in CVD, we will follow an innovative approach by using: 1. Independent and large-scale population studies from which novel targets with strong correlation to clinical phenotypes are deduced; 2. Translational disease-mimicking models (cellular and animal) to validate novel drug targets; 3. High quality human biobanks to confirm the molecular relevance of targets in diseased cardiovascular tissues; 4. A stringent pharmaceutical drug discovery process for prioritization of drugable targets. An important concept, in line with the changed pharmaceutical business model, is that these steps can best be executed by a functional network of clinical academic centers and specialized SMEs under the guidance of established and experienced drug discovery researchers from industry that brings together the right components and expertise to execute such a modular target discovery process."

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

NEDERLANDSE ORGANISATIE VOOR TOEGEPAST NATUURWETENSCHAPPELIJK ONDERZOEK TNO
Address
Anna Van Buerenplein 1
2595 DA Den Haag
Netherlands
Activity type
Research Organisations
EU contribution
€ 939 353
Administrative Contact
Alain Van Gool (Prof.)

Participants (12)

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Germany
EU contribution
€ 700 083
Address
Ingolstadter Landstrasse 1
85764 Neuherberg
Activity type
Research Organisations
Administrative Contact
Juergen Ertel (Dr.)
KAROLINSKA INSTITUTET
Sweden
EU contribution
€ 598 000
Address
Nobels Vag 5
17177 Stockholm
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Kindaker Therese (Mrs.)
ASTRAZENECA AB
Sweden
EU contribution
€ 250 112
Address
Vastra Maelarhamnen
151 85 Sodertaelje
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Eva Hurt-Camejo (Prof.)
HJARTAVERND SES
Iceland
EU contribution
€ 499 499
Address
Holtasmari 1
201 Kopavogur
Activity type
Research Organisations
Administrative Contact
Vilmundur Gudnason (Prof.)
ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
EU contribution
€ 300 720
Address
Albinusdreef 2
2333 ZA Leiden
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Jan Lindeman (Dr.)
CARDIOGENX BV
Netherlands
EU contribution
€ 701 024
Address
Lichtenauerlaan 30
3006AG Rotterdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Dharminder Chahal (Mr.)
POLYGENE AG
Switzerland
EU contribution
€ 697 930
Address
Riedmattstrasse 9
8153 Rümlang
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Doron Shmerling (Dr.)
BIONEER A/S
Denmark
EU contribution
€ 296 000
Address
Kogle Alle 2
2970 Hoersholm
Activity type
Research Organisations
Administrative Contact
Kim Holmström (Dr.)
IMABIOTECH SAS
France
EU contribution
€ 296 000
Address
152 Rue Du Docteur Yersin
59120 Loos
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jonathan Stauber (Mr.)
MORPHISTO EVOLUTIONSFORSCHUNG UND ANWENDUNG GMBH
Germany
EU contribution
€ 295 000
Address
Weismullerstrasse 45
60314 Frankfurt Am Main
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Michael Gudo (Dr.)
UMEA UNIVERSITET
Sweden
EU contribution
€ 200 000
Address
Universitetomradet
901 87 Umea
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Stefan Nilsson (Dr.)
MAARTEN DANIEL SOLLEWIJN GELPKE
United Kingdom
EU contribution
€ 199 800
Address
Sherbrooke Way 64
KT4 8BP Worcester Park Surrey
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Maarten Sollewijn Gelpke (Dr.)